1. Mazuski JE, Sawyer RG, Nathens AB, et al, for the Therapeutic Agents Committee of the Surgical Infections Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt). 2002;3:161-173.
2. Malangoni MA. Contributions to the management of intraabdominal infections. Am J Surg. 2005;190:255-259.
3. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of antiinfective agents for complicated intra-abdominal infections. Clin Infect Dis.
2003;37:997-1005.
4. Malangoni MA, Song J, Herrington J, Choudri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg. 2006;244:204-211.
5. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, for the Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005;41(suppl 5):S354-S367.
6. Drago M, Scaltrito MM, Morace G, for the GISIA-2 Group. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis. 2004;23:619-6